EN DE
Watch Allergy Therapeutics for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Allergy Therapeutics (AGY) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Allergy Therapeutics stock £0.01, price £0.01, that is 8.2% below the price, quality 27 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · ISIN GB00B02LCQ05

AT Allergy Therapeutics logo Thin data Nov 10, 2026

Allergy Therapeutics

AGY · LSE
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value £0.0129 · Fairly valued
Negative equity (buybacks among others)
Profit last quarter 56% below a year ago.
Quality 27/100
Weak Growth (revenue 5y −6.8 %/yr in GBP)
Loss-making · -84.1% net margin (TTM)
Negative free cash flow
Trails peers (2/7)
Narrow moat 10/100 · thin data
Thin data
Estimate⚠ Small free float
Watch Allergy Therapeutics for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£0.3850 £0.0088 Fair Value £0.0129 Feb 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range £0.0088 – £0.3850 · fair‑value band £0.0124 – £0.0133 · the £0.0140 price screens above the £0.0129 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Allergy Therapeutics in your weekly email

Every Wednesday you see whether Allergy Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally.

Show moreShow less

The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products.

Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus.

It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine.

Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.

Stock analysis

Allergy Therapeutics (AGY) currently trades at £0.0140, while our estimate is £0.0129, so the stock looks roughly fairly valued today (gap 8.9%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: £0.0124 (bear) to £0.0133 (bull), the price of £0.0140 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Allergy Therapeutics reported revenue of £55.0M in FY2025 versus £84.3M in FY2021, a compound −10.1%/yr. Reported net income was −£40.1M in FY2025.

Key figures

Market cap £253M Small · P/S ratio 4.42 · EPS (TTM) £−0.0100 · Net margin −84.1% · Return on equity −369% · Return on assets (EBIT) −32.7% (5-year average) · Operating margin −31.4% · Revenue (TTM) £57.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 88% below its 52-week high and 10% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −8%, AGY screens cheaper than that median.

Fair Value

Bear £0.0124 Fair Value £0.0129 Bull £0.0133
Price £0.0140 · Downside -8.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31
How much profit the company makes from its sales and capital
Quality Growth 39
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 21
Debt, balance sheet and risk of trouble
Investment 93
Does it invest with discipline instead of growing at any price?
Low Volatility 34
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−0.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.8%
Start year 2020 (pandemic). Over 10 years: +2.4% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
5.7% (2020) → −53.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch AGY, get fair value alerts →

Compare Allergy Therapeutics with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −7.9% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −59.4% · Bottom 25%
Net margin (12 months) −84.1% · Bottom 25%
Operating margin (12 months) −31.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 6.6% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 4.42× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)23 · sector 18
FUTURE (revenue growth)33 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 31

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs AGY
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs AGY
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs AGY
Haleon plc HLN $9.06 $8.62 −5% vs AGY
Merck KGaA MRK €149.35 €109.18 −27% vs AGY
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs AGY
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs AGY
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs AGY
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs AGY
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs AGY

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Allergy Therapeutics: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Allergy Therapeutics Fair Value". https://www.fairvalue-calculator.com/stock/AGY

Frequently asked questions

Is Allergy Therapeutics (AGY) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is £0.0129 versus a price of £0.0140, about 8% lower (fairly valued).
What is the fair value of AGY?
Our estimate for Allergy Therapeutics is £0.0129 (as of Nov 10, 2026), built from audited fundamentals. The current price: £0.0140.
What is the quality score of AGY?
Allergy Therapeutics has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Allergy Therapeutics (AGY)?
Our calculated price target is the estimate of £0.0129 (as of Nov 10, 2026). Cautious scenario £0.0124, optimistic scenario £0.0133. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Allergy Therapeutics stock forecast for 2026?
Our estimate puts fair value at £0.0129, about 8% lower versus a price of £0.0140 (fairly valued). Cautious scenario £0.0124, optimistic scenario £0.0133. The calculation is refreshed regularly with new filings.
What is the revenue of Allergy Therapeutics (AGY)?
Allergy Therapeutics reported trailing-twelve-month revenue of about £57.3M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Allergy Therapeutics (AGY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Allergy Therapeutics it is £0.0129 per share (as of Nov 10, 2026), against a price of £0.0140.
Is Allergy Therapeutics stock overvalued or undervalued in 2026?
As of Nov 10, 2026, AGY trades above its calculated fair value: price £0.0140, fair value £0.0129, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AGY?
No. The price is what the market pays today (£0.0140); the fair value is what the company's own numbers justify (£0.0129). For Allergy Therapeutics the two are £0.0011 per share apart. That gap is exactly why we show both numbers side by side.
How much is Allergy Therapeutics worth?
The market values Allergy Therapeutics at about £253M (market capitalisation, as of Nov 10, 2026). Per share that is £0.0140; our models calculate a fair value of £0.0129 per share.
What do the bullish and bearish scenarios say about AGY?
Our models span a range for Allergy Therapeutics: cautious scenario £0.0124, base £0.0129, optimistic £0.0133 per share (as of Nov 10, 2026, price £0.0140). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Allergy Therapeutics (AGY)?
Balance-sheet figures for Allergy Therapeutics (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is AGY from its 52-week high?
Allergy Therapeutics trades at £0.0140, about 88% below its 52-week high of £0.1210 and 10% above the low of £0.0128 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0129 is for.
Which stocks are comparable to Allergy Therapeutics?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Allergy Therapeutics stock attractive at the current price?
The data as of Nov 10, 2026: price £0.0140, calculated fair value £0.0129 (−8%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Allergy Therapeutics itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Allergy Therapeutics (AGY)?
The closing price on Nov 10, 2026 was £0.0140. Our estimate is £0.0129, about 8% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Allergy Therapeutics right now?
The price sits above even our optimistic bull case (£0.0133). The favourable scenario is already priced in. The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (£0.0124 to £0.0133), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Allergy Therapeutics

How large is the market capitalisation of Allergy Therapeutics (AGY)?
The market capitalisation of Allergy Therapeutics is £253M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Allergy Therapeutics (AGY)?
The price-to-sales ratio of Allergy Therapeutics is 4.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Allergy Therapeutics (AGY)?
Earnings per share at Allergy Therapeutics are £−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Allergy Therapeutics (AGY)?
The net margin of Allergy Therapeutics is −84.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Allergy Therapeutics (AGY)?
The return on equity (ROE) of Allergy Therapeutics is −369% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Allergy Therapeutics (AGY)?
On an EBIT basis the return on assets of Allergy Therapeutics is −32.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Allergy Therapeutics (AGY)?
The operating margin of Allergy Therapeutics is −31.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Allergy Therapeutics (AGY)?
Revenue at Allergy Therapeutics is growing +6.6% versus a year earlier (3y avg −8.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Allergy Therapeutics (AGY)?
Earnings per share at Allergy Therapeutics are growing −55.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Allergy Therapeutics (AGY) generate?
The free cash flow of Allergy Therapeutics is −£32.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Allergy Therapeutics (AGY) carry?
The net debt of Allergy Therapeutics is £47.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Allergy Therapeutics in the live analysis

One click puts Allergy Therapeutics on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.